tbuckley/cabot-search huggingface dataset:
OC-030 Defining the Unmet Need in Primary Sclerosing Cholangitis: The International PSC Group Risk Stratification Study
Authors: PJ Trivedi, TJ Weismuller, A Bergquist, GM Hirschfield, BE Hansen, KM Boberg
Journal: Gut (2016)

<h3>Introduction</h3> Primary sclerosing cholangitis (PSC) is a relatively uncommon hepatobiliary disorder associated with inflammatory bowel disease (IBD), wherein therapy other than transplantation remains ineffective. To understand disease course, within a goal of appropriately stratified care, the International PSC Study Group describes the natural history and clinical phenotypes across the largest cohort ever assembled. <h3>Methods</h3> We collected individual-patient data from 1980 to 2010 (37 centres, 17 countries) and conducted risk-assessment for commonly recognised phenotypic associations. <h3>Results</h3> Of 7,119 patients, 2,622 progressed to liver transplantation/death (LTD) (median 14·2 years) and 722 developed hepatobiliary malignancy (incidence rates: 47·5 and 13·7 per-1,000-patient-years, respectively). Cholangiocarcinoma was the most frequent malignancy (n = 596), with 38·1% of cases identified within 1 year of PSC diagnosis. Observing the patient cohort in entirety, the majority were men (65·5%), had classical/large-duct disease (89·5%), and developed IBD at some point (70·0%). IBD consistent with Crohn’s disease (vs. ulcerative colitis) or an absence of IBD over time conferred a lower risk of LTD (time-dependent, unadjusted hazard ratio (HR): 0·61, <i>p</i> &lt; 0.001; and HR:0·90, <i>p</i> = 0·03; respectively) and malignancy (unadj. HR:0·68, <i>p</i> = 0·007 and HR:0·77, <i>p</i> = 0·003; respectively), as did small-duct PSC (sdPSC) (unadj. HR:0·50, <i>p</i> &lt; 0·001 and HR:0·40, <i>p</i> &lt; 0·001; for LTD and malignancy, respectively) and female sex (unadj. HR:0·89, <i>p</i> = 0·018 and HR:0·70, <i>p</i> &lt; 0·001; for LTD and malignancy, respectively). On multivariable analyses assessing LTD, the impact of sdPSC over classical PSC persisted, with greater protection apparent for men (adjusted HR:0·31, <i>p</i> &lt; 0·001) than women (adj. HR:0·56, <i>p</i> = 0·009). However, women with classical PSC expressed a lower independent risk of disease progression than men of matched PSC subtype (adj. HR:0·9, <i>p</i> = 0.022). IBD-phenotype retained independent stratification properties of LTD, with Crohn’s disease and IBD-absence characterising lower-risk subgroups (time-dependent adj. HR:0·69 and HR:0·89, <i>p</i> &lt; 0·001 and <i>p</i> = 0.012; respectively). sdPSC (adj. HR:0·45, p = 0·02), Crohn’s disease (time-dependent adj. HR:0·72, p = 0·045), and IBD-absence (time-dependent adj. HR:0·72, p = 0·02) were also independently predictive of a lower HPB malignancy risk. <h3>Conclusion</h3> Using a robust, internationally representative cohort of unique size we demonstrate how distinct, clinically meaningful phenotypes stratify outcomes in PSC. We highlight the great-unmet need for patients, and provide risk markers clinically relevant to patient care and future trial design. <h3>Disclosure of Interest</h3> None Declared
Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM).
Authors: Luca Maurillo, Francesco Buccisano, Benedetta Neri, Carla Mazzone, Giovanni Del Poeta, Licia Ottaviani, Pasquale Niscola, Ilaria Del Principe, Anna Tamburini, Maria Irno Consalvo, Francesco Lo Coco, Sergio Amadori, Adriano Venditti
Journal: Blood (2005)
FRI0124 Nontuberculous Mycobacterial Infection in Rheumatoid Arthritis Patients: A Single-Center Experience in South Korea: Table 1.
Authors: D.-H. Lim, S.M. Ahn, S. Hong, W.J. Seo, Y.-G. Kim, C.-K. Lee, B. Yoo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The incidence of nontuberculous mycobacteria (NTM) infection has been increasing worldwide in both general population and in immunocompromised patients, including rheumatoid arthritis (RA) patients. However, most of previous studies focused on clinical features of NTM infection during treatment with anti-tumor necrosis factor (TNF) or were conducted in western countries, where NTM infection is more common than tuberculosis (TB) infection. <h3>Objectives</h3> The aims of our study were to identify the incidence and clinical characteristics of NTM infection in RA patients who live in the TB endemic area. <h3>Methods</h3> We performed a retrospective analysis of cases with NTM infection in the RA registry at a tertiary referral center from January 1995 to December 2013. The clinical features of the NTM cases were compared to those of 52 patients with TB infection. <h3>Results</h3> Among 1,397 patients with RA, NTM infection was newly developed in 26 (1.86%) patients and the incidence of NTM infection was 164.8 per 100,000 patient-years. The mycobacterium avium complex was the most frequent isolate (76.9%). None of the NTM infections had extrapulmonary involvement, which was rather common in TB infection (26.9%) (Table). Patients with NTM infection were older, received higher cumulative doses of corticosteroid, had higher rates of history of TB infection, and had higher incidence of concomitant interstitial lung disease (ILD) than cases with TB infection. <h3>Conclusions</h3> In South Korea, NTM infection is not rare in RA patients. Physicians should be cautious about NTM infection in patients with history of TB infection or concomitant ILD, even in endemic areas of TB. <h3>Disclosure of Interest</h3> None declared
Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Naveen Pemmaraju, Deborah Thomas, Hagop M. Kantarjian, Jorge E. Cortes, John T Manning, L. Jeffrey Medeiros, Susan O'Brien, Naval G. Daver, Aziz Nazha, Sherry A. Pierce, Guillermo Garcia-Manero, Elias J. Jabbour, Stefan Faderl
Journal: Blood (2012)
Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Authors: Erica D Warlick, Brian McClune, Tanya L. Pedersen, Kwang W Awn, Joseph H. Antin, Jean-Yves Cahn, Marcos DeLima, Vikas Gupta, David I Marks, Donald Bunjes, John F. DiPersio, Steven Devine, Daniel J. Weisdorf
Journal: Blood (2011)
Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Authors: Kevin Wood, Sergio A Giralt, Guenther Koehne, David Chung, Nikoletta Lendvai, Hani Hassoun, Alex Lesokhin, Elizabeth Hoover, Sean Devlin, Heather Landau
Journal: Blood (2012)
Differential Role of Myeloid Transcription Factors, C/EBPα and PU.1 In Leukemogenesis by MLL-Fusion Oncogenes.
Authors: Yumi Fukuchi, Kana Kuroda, Ken Sadahira, Ryouichi Ono, Daniel G. Tenen, Toshio Kitamura, Tetsuya Nosaka, Shinichiro Okamoto, Hideaki Nakajima
Journal: Blood (2010)
Mice with Genetic Modifications in Prothrombin Limiting Activation Cleavage Events to Meizothrombin Survive to Adulthood, but Exhibit Alterations in Hemostasis and Thrombus Formation
Authors: Eric S. Mullins, Maureen A. Shaw, Kathryn E. McElhinney, Keith W. Kombrinck, Matthew J. Flick, Alexander Brill, Denisa D. Wagner, Jay L. Degen
Journal: Blood (2012)
Relationship between Serum Concentrations and Urinary Excretions of Monoclonal Free Light Chains (mFLC) Detectable as Bence Jones Proteins (BJP) by Immunofixation Electrophoresis (IFE) in Patients with Multiple Myeloma (MM).
Authors: M.R. Nowrousian, D. Brandhorst, C. Sammet, M. Kellert, R. Daniels, P. Schuett, M. Poser, S. Mueller, P. Ebeling, A. Welt, U. Buttkereit, B. Opalka, M. Flasshove, S. Seeber, T. Moritz
Journal: Blood (2005)
Bing Neel Syndrome: The French Experience
Authors: Laurence Simon, Xavier Leleu, Jehan Dupuis, Therese Aurran, Lauris Gastaud, Carole Soussain, Beatrice Mahe, Stephane Lepretre, Borhane Slama, Guillaume Cartron, Charlotte Bonnet, Olivier Gisserot, Camille Payet, Veronique Leblond, Luc Fornecker
Journal: Blood (2014)
The Endothelial Protein C Receptor Supports TF-VIIa-Xa Ternary Complex Signaling through Protease-Activated Receptors.
Authors: Jennifer Disse, Helle Heibroch Petersen, Katrine S. Larsen, Egon Persson, Naomi Esmon, Charles Esmon, Lars C. Petersen, Luc Teyton, Wolfram Ruf
Journal: Blood (2010)
Field‐testing the new anaphylaxis' classification for the WHO International Classification of Diseases‐11 revision
Authors: L. K. Tanno, N. Molinari, S. Bruel, J.‐L. Bourrain, M. A. Calderon, P. Aubas, P. Demoly
Journal: Allergy (2016)

Abstract Background To consolidate the new classification model addressed to the allergic and hypersensitivity conditions according to the International Classification of Diseases ( ICD )‐11 revision timeline, we here propose real‐life application of quality assurance methodology to evaluate sensitivity and accuracy of the ‘Anaphylaxis’ subsection. Methods We applied field‐testing methodology by analysing all the consecutive inpatients’ files documented as allergies from the University Hospital of Montpellier electronic database for the period of 1 year. The files clinically validated as being anaphylaxis were manually blind‐coded under ICD ‐10 and current ICD ‐11 beta draft. The correspondence of coding and the impressions regarding sensibility were evaluated. Results From all 2318 files related to allergic or hypersensitivity conditions, 673 had some of the anaphylaxis ICD ‐10 codes; 309 files (46%) from 209 patients had anaphylaxis and allergic or hypersensitivity comorbidities description. The correspondence between the two coders was perfect for 162 codes from all 309 entities (52.4%) (Cohen‐kappa value 0.63) with the ICD ‐10 and for 221 codes (71.5%) (Cohen‐kappa value 0.77) with the ICD ‐11. There was a high agreement regarding sensibility of the ICD ‐11 usability (Cohen‐kappa value 0.75). Conclusion We here propose the first attempt of real‐life application to validate the new ICD ‐11 ‘Anaphylaxis’ subsection. Clearer was the improvement in accuracy reaching 71.5% of agreement when ICD ‐11 was used. By allowing all the relevant diagnostic terms for anaphylaxis to be included into the ICD ‐11 framework, WHO has recognized their importance not only to clinicians but also to epidemiologists, statisticians, healthcare planners and other stakeholders.
Gene-Specific Effects of the Histone Deacetylase Inhibitor TSA on Activation of a Pro-Inflammatory Endothelial Cell Phenotype by the Major Phagocyte Peroxidase-Derived Oxidant HOSCN.
Authors: Teena Pasrija, Shawn A Mahmud, John D Belcher, Gregory M. Vercellotti, Arne Slungaard
Journal: Blood (2008)
Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation
Authors: Marc Poch Martell, Jieun Uhm, Naheed Alam, Vikas Gupta, Jeffrey H. Lipton, John Kuruvilla, Matthew D. Seftel, Hans A. Messner, Dennis Kim
Journal: Blood (2014)
Classification of Non-Hodgkin Lymphoma in Seven Geographic Regions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project
Authors: Anamarija M. Perry, Diebold Jacques, Bharat N. Nathwani, Kenneth Angus Maclennan, H Konrad Müller-Hermelink, Eugene Boilesen, Martin Bast, James O. Armitage, Dennis D. Weisenburger
Journal: Blood (2015)
Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.
Authors: Corey Cutler, Shuli Li, Haesook T. Kim, Edwin Alyea, Vincent Ho, Stephanie J. Lee, David C. Fisher, Robert Schlossman, David Miklos, Robert Soiffer, Joseph H. Antin
Journal: Blood (2004)
The Reduced Lymphopoietic Potential of a Novel Subclass of Hematopoietic Stem Cells Is Mediated by Specific Defects In the Production and Activity of Their Common Lymphoid Progenitor (CLP) Progeny
Authors: Claudia Benz, Michael R Copley, David Kent, Stefan Woehrer, Keegan Rowe, Connie J. Eaves
Journal: Blood (2010)
Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry
Authors: Cristina Mecucci, Andrea Roncadori, Roberta La Starza, Francesco Arcioni, Alessandro Levis, Valeria Santini, Giuliana Alimena, Fabrizio Pane, Giuseppe Rossi, Maria Cantonetti, Anna D'Emilio, Nicola Di Renzo, Pietro Leoni, Giovanni Caocci, Alessandro Rambaldi, Paolo Avanzini, Giuseppe Visani, Sante Tura, Anna Covezzoli
Journal: Blood (2012)
Efficacy and Safety of Deferasirox (Exjade®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis
Authors: Maria Domenica Cappellini, Renzo Galanello, Antonio Piga, Alan Cohen, Antonis Kattamis, Yesim Aydinok, Paul Williamson, Lisa Rojkjaer, John B Porter
Journal: Blood (2008)
AB0375 Biosimilars in Rheumatology Clinical Practice- Gaining Acceptance in Developing World-Experience from South india:
Authors: S. Nallasivan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biologic disease modifying anti-rheumatic drugs (DMARD) have revolutionized the management of several rheumatic disorders. A decade of experience in the west has gained insights in to the safety and efficacy of these cytokine inhibitors in inflammatory rheumatological disorders. However, the access to biologics has been restricted by the cost, in the developing world. Bio-similars <sup>(1)</sup> have been developed in the Far East including India and the efficacy and safety have been comparable to their reference products, with affordable cost, with huge benefit to the patients. <h3>Objectives</h3> To review the use of synthetic DMARDs- Biosimilars in two centres of Rheumatology in south India and assess the efficacy/safety profile among the patients. <h3>Methods</h3> All Biologic users for a period of one year in the Rheumatology centre in Velammal Medical College Hospital, Madurai and Aruna Hospitals, Tirunelveli were reviewed (Oct 14-Oct 15). All patients should satisfy ACR criteria for diagnosis and would have failed classic DMARDs. They were all screened for TB, Hepatitis as per UK-NICE guidelines. All had 3 months review and are under regular follow up. <h3>Results</h3> Data from 15 patients were collected in this retrospective review. (Indications below) All 7 patients with RA were Bio-naive, received the biosynthetic DMARDS and achieved remission in 3 months. Pre treatment average DAS score was 5.65 and 3 months following treatment, the average DAS 28 score was 2.01, which shows significant improvement. The girl with SLE has responded dramatically following Mabtas therapy. In the Spondyloarthropathy group, all but one had spinal disease only. Pre treatment average BASDAI was 6.64 and 3 months following biosimilars BASDAI was 2.6. To date no infective complications were reported. All are maintained on oral DMARDS either Methotrexate or Leflunomide without steroids. <h3>Conclusions</h3> Biosimilars have been developed in the developing world with affordable cost. They are increasingly being used in different complex inflammatory rheumatologic diseases. It has gained reasonable acceptance. The rheumatologist should be aware of safety and use in a diligent manner. <h3>References</h3> Thomas Dorner and Jonathan Kay. Biosimilars in rheumatology: current perspectives and lessons learnt. Nature Reviews Rheumatology 2015. Pages 713–724. <h3>Acknowledgement</h3> Special thanks to all the patients and The Velammal hospital rheumatology and medicine team. <h3>Disclosure of Interest</h3> None declared
STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23
Authors: Michael W Bösl, Elisa Osterode, Deepak Bararia, Alessandro Pastore, Anette M Staiger, German Ott, Monika Szczepanowski, Wolfram Klapper, Andreas Rosenwald, Wolfgang Hiddemann, Oliver Weigert
Journal: Blood (2015)
Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.
Authors: Michael Deininger, François-Xavier Mahon, Francois Guilhot, Giuseppe Saglio, Philipp le Coutre, Arnon Nagler, Anna D'Emilio, Fabio Stagno, Enrica Morra, Andrea Piccin, Sarit E. Assouline, Elisabetta Abruzzese, Valeria Santini, Fabrizio Pane, Pilar Giraldo, Laura Antolini, Maria Grazia Valsecchi, Carlo Gambacorti-Passerini
Journal: Blood (2009)
Rudolf Virchow: Doctor, Statesman, Anthropologist
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of VWD Patients Requiring Elective Surgery with a Pasteurized von Willebrand Factor/FVIII Concentrate (Haemate®P) - The Use of a PK Guided Approach.
Authors: Pier M. Mannucci, P. Kyrle, M. Holmstroem, S. Haertel, S. Knaub, S. Lethagen
Journal: Blood (2005)
Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children’s Oncology Group (COG) Study (AALL03N1)
Authors: Lindsey Hageman, Wendy Landier, Yanjun Chen, Heeyoung Kim, Nancy Kornegay, William E. Evans, Bruce C. Bostrom, Jacqueline Casillas, David Dickens, Anne Angiolillo, Glen Lew, Kelly Maloney, Leo Mascarenhas, Arthur K. Ritchey, Amanda Termuhlen, William L. Carroll, Mary V. Relling, F. Lennie Wong, Smita Bhatia
Journal: Blood (2014)
PTU-002 EUS-Guided Insertion of Fully Covered Self-Expandable Metal Stents for Drainage of Pancreatic Walled-Off Necrosis Does Not Require Fluoroscopy
Authors: B Braden, A Koutsoumpas, M Silva, Z Soonawalla, CF Dietrich
Journal: Gut (2016)

<h3>Introduction</h3> Transgastric placement of specially designed fully covered self-expandable metal stent (FCSMS) has improved the management and the outcome of walled-off necrosis (WON) after severe pancreatitis. Reduction of radiation exposure is of increasing importance. Therefore, we investigated whether transgastric insertion of FCMS for drainage of WON is possible only by EUS-guidance. <h3>Methods</h3> Patients with symptomatic pancreatic walled-off necrosis referred for endoscopic drainage were included. EUS-guided stent insertion was performed under concious sedation or endotracheal intubation. The pancreatic collection was accessed from the stomach using a linear echoendoscope with a 19 G access needle, a cystotome or directly using the hot Axios® device. After insertion of a guidewire and enlargement of the transgastric access by diathermy a fully covered self-expandable metal stent was inserted under EUS guidance without fluoroscopy. As clinically indicated, endoscopic necrosectomy was performed through the large diameter metal stent. When the collection had shrunk to less than 4 cm, symptoms and inflammatory parametrs had improved, the stent was endoscopically removed. <h3>Results</h3> 18 patients (median age: 55 years; range 48–63 years) with symptomatic WON (median diameter: 14 cm; range 8–18 cm) were referred for EUS-guided drainage. In 2 patients large traversing arteries within the cavity were detected by colour Doppler imaging during EUS, therefore the insertion of FCSMS was not attempted to avoid possible erosion of the vessels by the stent edges with reducing collection size. In all other patients (88.9%) the completely EUS-guided transgastric stent insertion without fluoroscopy was technically successful (6 AXIOS<sup>®</sup> and 10 Nagi<sup>®</sup> stents were inserted). The stent insertion into the cavity and the opening of the distal flange could be clearly visualised by EUS in all cases. After correct positioning of the FCSMS by EUS the proximal stent flange was deployed under endoscopic guidance. Two patients were readmitted with fever when the stent was blocked with debris. Seven patients required endoscopic necrosectomy through the FCSMS. One patient developed self-limiting bleeding. WON resolved in all patients within 8 weeks. <h3>Conclusion</h3> The good sonographic visibility of the FCSMS throughout the procedure allows safe and easy insertion of transgastric drainage under EUS-guidance without fluoroscopy. <h3>Reference</h3> 1 Seifert H, Wehrmann T, Schmitt T, Zeuzem S, Caspary WF. Retroperito-neal endoscopic debridement for infected peripancreatic necrosis. Lancet 2000; <b>356</b>:653–5. <h3>Disclosure of Interest</h3> None Declared
Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia
Authors: Tasneem Motiwala, Satavisha Roy, Shujun Liu, Sebastian Schwind, Rainer Claus, Xiaokui Mo, Ramiro Garzon, Hartmut Dohner, Konstanze Dohner, David Jarjoura, Christoph Plass, Guido Marcucci, Samson T. Jacob
Journal: Blood (2012)
At Equal Doses FIXFc (Alprolix) Is Not Significanly Better in a Saphenous Vein Bleeding Model Than Recombinant FIX (BeneFix) Seven Days Post-Infusion
Authors: Brian Cooley, David M Mann, Dougald Monroe, Feng-Chang Lin, Paul E. Monahan, Darrel W. Stafford
Journal: Blood (2015)
In Vitro Induction of Anti-Leukemia CTL Effect by Dendritic Cells Infected with Recombinant Adenovirus Vectors Containing Human Survivin Genes.
Authors: Xiongpeng Zhu, Jianda Hu, Xu Lin, Ting Yang, Zhengshu Xu, Lulu Lv, Chuntuan Li, Zhizhe Chen
Journal: Blood (2006)
Paradoxical Dose-Dependent Chemoattractive and Chemorepellent Effects of Kit Ligand (KL) In Mast Cells Revealed In Novel Microfluidic Biochambers.
Authors: Amir Shamloo, Milan Manchandia, Maheswaran Mani, Christopher Nguyen, Thomas Jahn, Kenneth I. Weinberg, Sarah Heilshorn
Journal: Blood (2010)
Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
Authors: Hyeyoung Yang, Seo Ree Kim, Myeong Jun Song
Journal: Clinical and Molecular Hepatology (2016)

Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban.